Transgelin-2
TAGLN2proteinTAGLN2 dysregulation in ACS platelets reflects aberrant cytoskeletal remodeling in atherothrombotic activation.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationalePlatelet dysregulation in ACS; upregulated in atherothrombotic disease; CAD-associated target.
Also acts inVascular inflammation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000158710
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Proteomic insights into the associations between obesity, lifestyle factors, and coronary artery disease.BMC medicine · 2023 · PMID 38049831 · doi
- Variations in Blood Platelet Proteome and Transcriptome Revealed Altered Expression of Transgelin-2 in Acute Coronary Syndrome Patients.International journal of molecular sciences · 2022 · PMID 35683019 · doi